Global Oligonucleotide-based Therapies Market Growth (Status and Outlook) 2025-2031
Description
According to this study, the global Oligonucleotide-based Therapies market size will reach US$ 9362 million by 2031.
Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.
Biogen is the industry"s biggest player, with more than 76 percent of 2018 revenue, followed by Sarepta Therapeutics and Jazz Pharmaceuticals, with 13.35 percent and 6.63 percent, respectively. North America and Europe are the most important regions, accounting for more than 80 percent of the combined income.
LPI (LP Information)' newest research report, the “Oligonucleotide-based Therapies Industry Forecast” looks at past sales and reviews total world Oligonucleotide-based Therapies sales in 2024, providing a comprehensive analysis by region and market sector of projected Oligonucleotide-based Therapies sales for 2025 through 2031. With Oligonucleotide-based Therapies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oligonucleotide-based Therapies industry.
This Insight Report provides a comprehensive analysis of the global Oligonucleotide-based Therapies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Oligonucleotide-based Therapies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oligonucleotide-based Therapies market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oligonucleotide-based Therapies and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oligonucleotide-based Therapies.
This report presents a comprehensive overview, market shares, and growth opportunities of Oligonucleotide-based Therapies market by product type, application, key players and key regions and countries.
Segmentation by Type:
Antisense Oligonucleotide
Aptamer
Other
Segmentation by Application:
Neuromuscular Diseases
Hepatic VOD
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics
Please note: The report will take approximately 2 business days to prepare and deliver.
Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.
Biogen is the industry"s biggest player, with more than 76 percent of 2018 revenue, followed by Sarepta Therapeutics and Jazz Pharmaceuticals, with 13.35 percent and 6.63 percent, respectively. North America and Europe are the most important regions, accounting for more than 80 percent of the combined income.
LPI (LP Information)' newest research report, the “Oligonucleotide-based Therapies Industry Forecast” looks at past sales and reviews total world Oligonucleotide-based Therapies sales in 2024, providing a comprehensive analysis by region and market sector of projected Oligonucleotide-based Therapies sales for 2025 through 2031. With Oligonucleotide-based Therapies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oligonucleotide-based Therapies industry.
This Insight Report provides a comprehensive analysis of the global Oligonucleotide-based Therapies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Oligonucleotide-based Therapies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oligonucleotide-based Therapies market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oligonucleotide-based Therapies and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oligonucleotide-based Therapies.
This report presents a comprehensive overview, market shares, and growth opportunities of Oligonucleotide-based Therapies market by product type, application, key players and key regions and countries.
Segmentation by Type:
Antisense Oligonucleotide
Aptamer
Other
Segmentation by Application:
Neuromuscular Diseases
Hepatic VOD
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
92 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Oligonucleotide-based Therapies Market Size by Player
- 4 Oligonucleotide-based Therapies by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Oligonucleotide-based Therapies Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
